car2 anti-cd38 a2 car-t cells
Cell therapyexperimental
Clinical trial activity
1 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Apr 5, 2018 (NCT03464916)
Timeline
2010s
- Jan 1, 2018
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1Immunity, passive
CD38 immunity, passive
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03464916 | Phase 1 | Apr 5, 2018 | Sorrento Therapeutics, Inc., University of Pennsylvania |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Sorrento Therapeutics, Inc. | For profit | 1 | 1 | 1 | 2018 |
| University of Pennsylvania | Academic/Hospital | 1 | 0 | 1 | 2018 |
2 organizations
Page 1 / 1